New hope for pancreatic cancer: targeted drug plus chemo in major trial
Disease control
Not yet recruiting
This phase 3 study tests whether adding the experimental drug FG-M108 to standard chemotherapy helps people with a specific type of advanced pancreatic cancer live longer. About 524 adults whose tumors have a protein called Claudin18.2 will receive either FG-M108 or a placebo alo…
Phase: PHASE3 • Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd • Aim: Disease control
Last updated May 07, 2026 18:39 UTC